A carregar...

An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma

Aberrant cell cycle progression is a hallmark feature of cancer cells. Cyclin-dependent kinases 4 and 6 (CDK4/6) drive progression through the G1 stage of the cell cycle, at least in part, by inactivating the tumor suppressor, retinoblastoma (RB). CDK4/6 are targetable and the selective CDK4/6 inhib...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Teh, Jessica L.F., Purwin, Timothy J., Greenawalt, Evan J., Chervoneva, Inna, Goldberg, Allison, Davies, Michael A., Aplin, Andrew E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5026598/
https://ncbi.nlm.nih.gov/pubmed/27488531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-3384
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!